LIVIVO - Search results -

Search results

Result 1 - 10 of total 45

Search options

Article ; Online: Correction: Identification of cytotoxic T cells and their T cell receptor sequences targeting COVID-19 using MHC class I-binding peptides.

Hikichi, Tetsuro / Sakamoto, Michiko / Harada, Makiko / Saito, Maki / Yamane, Yuka / Tokumura, Kimihisa / Nakamura, Yusuke

Journal of human genetics

2022 Volume 67, Issue 7, Page(s) 445–446

Language	English
Publishing date	2022-02-10
Publishing country	England
Document type	Published Erratum
ZDB-ID	1425192-9
ISSN	1435-232X ; 1434-5161
ISSN (online)	1435-232X
ISSN	1434-5161
DOI	10.1038/s10038-022-01024-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 201: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Identification of cytotoxic T cells and their T cell receptor sequences targeting COVID-19 using MHC class I-binding peptides.

Hikichi, Tetsuro / Sakamoto, Michiko / Harada, Makiko / Saito, Maki / Yamane, Yuka / Tokumura, Kimihisa / Nakamura, Yusuke

Journal of human genetics

2022 Volume 67, Issue 7, Page(s) 411–419

Abstract: Since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) was first reported in China in December 2019, various variants have been identified in different areas of the world such as United Kingdom (alpha), South Africa (beta and ... ...

Abstract	Since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) was first reported in China in December 2019, various variants have been identified in different areas of the world such as United Kingdom (alpha), South Africa (beta and omicron), Brazil (gamma), and India (delta). Some of SARS-CoV-2 variants, each of which is characterized by a unique mutation(s) in spike protein, are concerned due to their high infectivity and the capability to escape from neutralizing antibodies elicited by vaccinations. To identify peptide epitopes that are derived from SARS-CoV-2 viral proteins and possibly induce CD8
MeSH term(s)	CD8-Positive T-Lymphocytes ; COVID-19 ; Epitopes, T-Lymphocyte/genetics ; HLA-A Antigens ; Humans ; Peptides/chemistry ; Receptors, Antigen, T-Cell ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus/genetics ; T-Lymphocytes, Cytotoxic
Chemical Substances	Epitopes, T-Lymphocyte ; HLA-A Antigens ; Peptides ; Receptors, Antigen, T-Cell ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2
Language	English
Publishing date	2022-02-02
Publishing country	England
Document type	Journal Article
ZDB-ID	1425192-9
ISSN	1435-232X ; 1434-5161
ISSN (online)	1435-232X
ISSN	1434-5161
DOI	10.1038/s10038-022-01013-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 201: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Second-Generation Antipsychotic Long-Acting Injection Reduced the Time of Restrictive Interventions in Patients With Schizophrenia: Retrospective, A 4-Year Mirror-Image Study.

Horikoshi, Sho / Miura, Itaru / Mui, Akihiro / Hikichi, Takeshi / Aono, Tetsuro / Hoshino, Ken-Yo / Terayama, Kenji / Yabe, Hirooki

Journal of clinical psychopharmacology

2022 Volume 42, Issue 6, Page(s) 526–529

Abstract: Background: Whether second-generation antipsychotic long-acting injection (SGA-LAI) reduces psychotic symptoms at relapse compared with oral antipsychotics remains unclear. The present study investigated the effects of SGA-LAI on the time (in hours) of ... ...

Abstract	Background: Whether second-generation antipsychotic long-acting injection (SGA-LAI) reduces psychotic symptoms at relapse compared with oral antipsychotics remains unclear. The present study investigated the effects of SGA-LAI on the time (in hours) of restrictive interventions in hospitalization by conducting a retrospective observational 4-year mirror-image study at a single medical center in Japan. Method: We performed a retrospective observational mirror-image study conducted between November 2013 and January 2018. Data were initially retrieved from 101 patients. The 38 patients with schizophrenia who met the inclusion criteria were enrolled in the analysis. The primary outcome was the time of restrictive interventions and the secondary outcomes included the number of hospitalizations (total, voluntary, and involuntary) and bed days compared 2 years before and after initiating SGA-LAI. The restrictive interventions were defined as seclusion and physical restraints. Results: The mean time of restrictive interventions significantly decreased from 43.7 to 3.03 ( P = 0.021). The number of admissions and the total number of bed days in post-SGA-LAI fell from 1.03 to 0.61 ( P = 0.011) and 130 to 39.3 ( P = 0.003), respectively, compared with pre-SGA-LAI. In particular, the number of involuntary admissions was significantly reduced (0.50-0.26, P = 0.039). Conclusions: The findings indicate that SGA-LAI reduced the time of restrictive interventions and the number of involuntary admissions. Moreover, SGA-LAI may contribute to mild psychiatric symptoms during relapse.
MeSH term(s)	Humans ; Antipsychotic Agents/pharmacology ; Antipsychotic Agents/therapeutic use ; Delayed-Action Preparations/therapeutic use ; Recurrence ; Retrospective Studies ; Schizophrenia/drug therapy
Chemical Substances	Antipsychotic Agents ; Delayed-Action Preparations
Language	English
Publishing date	2022-09-03
Publishing country	United States
Document type	Journal Article ; Observational Study
ZDB-ID	604631-9
ISSN	1533-712X ; 0271-0749
ISSN (online)	1533-712X
ISSN	0271-0749
DOI	10.1097/JCP.0000000000001599
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1664: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Significance of Contact Force on Esophageal Thermal Injury During Relative High-Power Short-Duration Ablation of Atrial Fibrillation.

Kaneshiro, Takashi / Amami, Kazuaki / Hijioka, Naoko / Nodera, Minoru / Yamada, Shinya / Yokokawa, Tetsuro / Misaka, Tomofumi / Hikichi, Takuto / Yoshihisa, Akiomi / Takeishi, Yasuchika

Circulation. Arrhythmia and electrophysiology

2021 Volume 14, Issue 6, Page(s) e009897

MeSH term(s)	Atrial Fibrillation/physiopathology ; Atrial Fibrillation/surgery ; Burns/diagnosis ; Burns/etiology ; Catheter Ablation/adverse effects ; Esophagus/injuries ; Female ; Follow-Up Studies ; Humans ; Intraoperative Complications ; Male ; Middle Aged ; Pulmonary Veins/surgery ; Time Factors
Language	English
Publishing date	2021-06-11
Publishing country	United States
Document type	Letter
ZDB-ID	2426129-4
ISSN	1941-3084 ; 1941-3149
ISSN (online)	1941-3084
ISSN	1941-3149
DOI	10.1161/CIRCEP.121.009897
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6667: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma.

Tamura, Ryota / Morimoto, Yukina / Sato, Mizuto / Hikichi, Tetsuro / Yoshida, Kazunari / Toda, Masahiro

Vaccines

2020 Volume 8, Issue 3

Abstract: Anti-angiogenic therapy, targeting vascular endothelial growth factor (VEGF)-A/VEGF receptors (VEGFRs), is beneficial for tumor growth prevention in a malignant glioma. A simultaneous blockade using both bevacizumab (Bev), which targets circulating VEGF- ... ...

Abstract	Anti-angiogenic therapy, targeting vascular endothelial growth factor (VEGF)-A/VEGF receptors (VEGFRs), is beneficial for tumor growth prevention in a malignant glioma. A simultaneous blockade using both bevacizumab (Bev), which targets circulating VEGF-A, and a multi-kinase inhibitor on VEGFRs was more effective for advanced solid cancers, including melanoma and renal cell carcinoma. However, previous clinical trials demonstrated a high adverse event rate. Additionally, no studies previously assessed treatment efficacy and safety using both VEGF-A and VEGFR-targeted agents for malignant gliomas. We had conducted clinical trials investigating VEGFRs peptide vaccination in patients with malignant gliomas, in which the treatment exhibited safety and yielded therapeutic effects in some patients. The combined use of Bev and VEGFRs vaccination may enhance the anti-tumor effect in malignant gliomas. In this pilot study, the adverse event profile in patients treated with Bev after the vaccination was investigated to establish this treatment strategy, in comparison to those treated with Bev collected from the published data or treated with the vaccination alone. In our previous clinical studies on patients with malignant gliomas, Bev was administered to 13 patients after VEGFRs vaccinations. One patient had a Grade 4 pulmonary embolism. Two patients had Grade 2 cerebral infarctions. There were no significant differences in the adverse event rates among patients treated with Bev, with the vaccination, or with Bev after the vaccination. Although careful observation is imperative for patients after this combination treatment strategy, VEGFRs-targeted vaccination may coexist with Bev for malignant gliomas.
Language	English
Publishing date	2020-09-02
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2703319-3
ISSN	2076-393X
ISSN	2076-393X
DOI	10.3390/vaccines8030498
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Clinical Trial of a Cancer Vaccine Targeting VEGF and KIF20A in Advanced Biliary Tract Cancer.

Murahashi, Mutsunori / Tsuruta, Toshihisa / Yamada, Kazunari / Hijikata, Yasuki / Ogata, Hisanobu / Kishimoto, Junji / Yoshimura, Sachiko / Hikichi, Tetsuro / Nakanishi, Yoichi / Tani, Kenzaburo

Anticancer research

2021 Volume 41, Issue 3, Page(s) 1485–1496

Abstract: Background: As the prognosis of biliary tract cancer (BTC) is extremely poor and treatment options are limited, new treatment modalities are urgently needed. We designed a phase II clinical trial to investigate the immune responses and clinical benefits ...

Abstract	Background: As the prognosis of biliary tract cancer (BTC) is extremely poor and treatment options are limited, new treatment modalities are urgently needed. We designed a phase II clinical trial to investigate the immune responses and clinical benefits of OCV-C01, an HLA-A24:02-restricted three-peptide cancer vaccine targeting VEGFR1, VEGFR2, and KIF20A. Patients and methods:* Participants were patients with advanced BTC who had unresectable tumours and were refractory to standard chemotherapy. OCV-C01 was injected weekly until the discontinuance criteria were met. Results: Six participants, including four patients positive for HLA-A24:02, were enrolled in this study for assessment of efficacy. Four out of six patients exhibited vaccine-specific T-cell responses to one or more of three antigens. Log-rank tests revealed that vaccine-specific T cell responses contributed significantly to overall survival. Conclusion:* The cancer vaccine had positive effects on survival, indicating that this approach warrants further clinical studies.
MeSH term(s)	Aged ; Aged, 80 and over ; Biliary Tract Neoplasms/drug therapy ; Biliary Tract Neoplasms/immunology ; Biliary Tract Neoplasms/metabolism ; Cancer Vaccines/administration & dosage ; Cancer Vaccines/adverse effects ; Cancer Vaccines/immunology ; Disease-Free Survival ; Female ; Fever/chemically induced ; Headache/chemically induced ; Humans ; Kinesin/antagonists & inhibitors ; Kinesin/immunology ; Male ; Middle Aged ; Molecular Targeted Therapy/methods ; Prognosis ; T-Lymphocytes, Cytotoxic/drug effects ; T-Lymphocytes, Cytotoxic/immunology ; T-Lymphocytes, Cytotoxic/metabolism ; Vaccines, Subunit/administration & dosage ; Vaccines, Subunit/adverse effects ; Vaccines, Subunit/immunology ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Vascular Endothelial Growth Factor A/immunology ; Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors ; Vascular Endothelial Growth Factor Receptor-2/immunology
Chemical Substances	Cancer Vaccines ; KIF20A protein, human ; OCV-C01 ; Vaccines, Subunit ; Vascular Endothelial Growth Factor A ; KDR protein, human (EC 2.7.10.1) ; Vascular Endothelial Growth Factor Receptor-2 (EC 2.7.10.1) ; Kinesin (EC 3.6.4.4)
Language	English
Publishing date	2021-03-31
Publishing country	Greece
Document type	Clinical Trial, Phase II ; Journal Article
ZDB-ID	604549-2
ISSN	1791-7530 ; 0250-7005
ISSN (online)	1791-7530
ISSN	0250-7005
DOI	10.21873/anticanres.14907
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1642: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: HIV-1 matrix mutations that alter gag membrane binding modulate mature core formation and post-entry events

Hikichi, Yuta / Takeda, Eri / Fujino, Masayuki / Nakayama, Emi / Matano, Tetsuro / Murakami, Tsutomu

Virology. 2019 June, v. 532

2019

Abstract: The matrix (MA) domain of HIV-1 Gag directs membrane binding of the Gag precursor polyprotein during the late events of virus replication. However, the effects of alteration in Gag membrane binding early post-infection are not well understood. To ... ...

Abstract	The matrix (MA) domain of HIV-1 Gag directs membrane binding of the Gag precursor polyprotein during the late events of virus replication. However, the effects of alteration in Gag membrane binding early post-infection are not well understood. To investigate impacts of MA mutations that alter Gag membrane binding on the phenotypes of newly produced virus particles, we extensively characterized two MA mutants by virological, biochemical, and morphological approaches. The V6R mutation, which decreases Gag membrane binding, modified Gag processing and core morphogenesis and impaired core uncoating, reverse transcription, and viral DNA integration. On the other hand, the L20K mutation, which increases Gag membrane binding, primarily decreased integrated DNA levels without affecting the viral components and morphology. These data suggest that HIV-1 MA plays roles in functional core formation and the following post-entry steps of the virus replication cycle. (140/150 words).
Keywords	DNA ; Human immunodeficiency virus 1 ; morphogenesis ; mutants ; mutation ; phenotype ; polyproteins ; reverse transcription ; virion ; virus replication
Language	English
Dates of publication	2019-06
Size	p. 97-107.
Publishing place	Elsevier Inc.
Document type	Article
ZDB-ID	200425-2
ISSN	1096-0341 ; 0042-6822
ISSN (online)	1096-0341
ISSN	0042-6822
DOI	10.1016/j.virol.2019.04.013
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Bonn / Germany

Z 3686: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma

Ryota Tamura / Yukina Morimoto / Mizuto Sato / Tetsuro Hikichi / Kazunari Yoshida / Masahiro Toda

Vaccines, Vol 8, Iss 498, p

2020 Volume 498

Abstract	Anti-angiogenic therapy, targeting vascular endothelial growth factor (VEGF)-A/VEGF receptors (VEGFRs), is beneficial for tumor growth prevention in a malignant glioma. A simultaneous blockade using both bevacizumab (Bev), which targets circulating VEGF-A, and a multi-kinase inhibitor on VEGFRs was more effective for advanced solid cancers, including melanoma and renal cell carcinoma. However, previous clinical trials demonstrated a high adverse event rate. Additionally, no studies previously assessed treatment efficacy and safety using both VEGF-A and VEGFR-targeted agents for malignant gliomas. We had conducted clinical trials investigating VEGFRs peptide vaccination in patients with malignant gliomas, in which the treatment exhibited safety and yielded therapeutic effects in some patients. The combined use of Bev and VEGFRs vaccination may enhance the anti-tumor effect in malignant gliomas. In this pilot study, the adverse event profile in patients treated with Bev after the vaccination was investigated to establish this treatment strategy, in comparison to those treated with Bev collected from the published data or treated with the vaccination alone. In our previous clinical studies on patients with malignant gliomas, Bev was administered to 13 patients after VEGFRs vaccinations. One patient had a Grade 4 pulmonary embolism. Two patients had Grade 2 cerebral infarctions. There were no significant differences in the adverse event rates among patients treated with Bev, with the vaccination, or with Bev after the vaccination. Although careful observation is imperative for patients after this combination treatment strategy, VEGFRs-targeted vaccination may coexist with Bev for malignant gliomas.
Keywords	bevacizumab ; VEGF-A ; VEGFR ; peptide vaccine ; adverse event ; malignant glioma ; Medicine ; R
Subject code	616 ; 610
Language	English
Publishing date	2020-09-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: HIV-1 matrix mutations that alter gag membrane binding modulate mature core formation and post-entry events.

Hikichi, Yuta / Takeda, Eri / Fujino, Masayuki / Nakayama, Emi / Matano, Tetsuro / Murakami, Tsutomu

Virology

2019 Volume 532, Page(s) 97–107

Abstract	The matrix (MA) domain of HIV-1 Gag directs membrane binding of the Gag precursor polyprotein during the late events of virus replication. However, the effects of alteration in Gag membrane binding early post-infection are not well understood. To investigate impacts of MA mutations that alter Gag membrane binding on the phenotypes of newly produced virus particles, we extensively characterized two MA mutants by virological, biochemical, and morphological approaches. The V6R mutation, which decreases Gag membrane binding, modified Gag processing and core morphogenesis and impaired core uncoating, reverse transcription, and viral DNA integration. On the other hand, the L20K mutation, which increases Gag membrane binding, primarily decreased integrated DNA levels without affecting the viral components and morphology. These data suggest that HIV-1 MA plays roles in functional core formation and the following post-entry steps of the virus replication cycle. (140/150 words).
MeSH term(s)	Cell Line, Tumor ; Cell Membrane/metabolism ; Cell Membrane/virology ; Gene Expression ; HEK293 Cells ; HIV-1/genetics ; HIV-1/growth & development ; HIV-1/metabolism ; Humans ; Lymphocytes/metabolism ; Lymphocytes/virology ; Mutation ; Protein Binding ; Protein Domains ; Protein Precursors/chemistry ; Protein Precursors/genetics ; Protein Precursors/metabolism ; Reverse Transcription ; Viral Matrix Proteins/chemistry ; Viral Matrix Proteins/genetics ; Viral Matrix Proteins/metabolism ; Virion/genetics ; Virion/growth & development ; Virion/metabolism ; Virus Assembly/genetics ; Virus Integration/genetics ; Virus Replication/genetics ; gag Gene Products, Human Immunodeficiency Virus/chemistry ; gag Gene Products, Human Immunodeficiency Virus/genetics ; gag Gene Products, Human Immunodeficiency Virus/metabolism
Chemical Substances	Protein Precursors ; Viral Matrix Proteins ; gag Gene Products, Human Immunodeficiency Virus
Language	English
Publishing date	2019-04-27
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	200425-2
ISSN	1096-0341 ; 0042-6822
ISSN (online)	1096-0341
ISSN	0042-6822
DOI	10.1016/j.virol.2019.04.013
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.172: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Characteristics of Esophageal Injury in Ablation of Atrial Fibrillation Using a High-Power Short-Duration Setting.

Kaneshiro, Takashi / Kamioka, Masashi / Hijioka, Naoko / Yamada, Shinya / Yokokawa, Tetsuro / Misaka, Tomofumi / Hikichi, Takuto / Yoshihisa, Akiomi / Takeishi, Yasuchika

Circulation. Arrhythmia and electrophysiology

2020 Volume 13, Issue 10, Page(s) e008602

Abstract: Background: The mechanism of esophageal thermal injury (ETI; esophageal mucosal injury and periesophageal nerve injury leading to gastric hypomotility) remains unknown when using a high-power short-duration (HP-SD) setting. This study sought to evaluate ...

Abstract	Background: The mechanism of esophageal thermal injury (ETI; esophageal mucosal injury and periesophageal nerve injury leading to gastric hypomotility) remains unknown when using a high-power short-duration (HP-SD) setting. This study sought to evaluate the characteristics of esophageal injuries in atrial fibrillation ablation using a HP-SD setting. Methods: After exclusion of 5 patients with their esophagus at the right portion of left atrium and 21 patients with additional ablations such as box isolation and low voltage area ablation in left atrium posterior wall, 271 consecutive patients (62±10 years, 56 women) who underwent pulmonary vein isolation by radiofrequency catheter ablation were analyzed. In the 101 patients, a HP-SD setting at 45 to 50 W with an Ablation Index module was used (HP-SD group). In the remaining 170 patients before introduction of the HP-SD setting, a conventional power setting of 20 to 30 W with contact force monitoring was used (conventional group). We performed esophagogastroduodenoscopy after pulmonary vein isolation in all patients and investigated the incidence and characteristics of ETI. Results: Although the incidence of ETI was significantly higher in the HP-SD group compared with the conventional group (37% versus 22%, Conclusions: Although the use of the HP-SD setting was a strong predictor of ETI, it could avoid deeper thermal injuries that reach the esophageal mucosal layer.
MeSH term(s)	Aged ; Atrial Fibrillation/surgery ; Burns, Electric/epidemiology ; Burns, Electric/pathology ; Catheter Ablation/adverse effects ; Endoscopy, Digestive System ; Esophagus/injuries ; Esophagus/pathology ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Prevalence ; Pulmonary Veins/surgery ; Risk Assessment ; Risk Factors ; Treatment Outcome
Language	English
Publishing date	2020-09-11
Publishing country	United States
Document type	Comparative Study ; Journal Article ; Observational Study
ZDB-ID	2426129-4
ISSN	1941-3084 ; 1941-3149
ISSN (online)	1941-3084
ISSN	1941-3149
DOI	10.1161/CIRCEP.120.008602
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6667: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito